The US Food and Drug Administration has approved Zinteglo, a drug developed by the Bluebird Bio company for gene therapy of one of the rare types of anemia.

Axar.az informs that this was reported by Reuters.

"There are about 1,500 people with beta thalassemia in the United States who could start treatment with Zinteglo by the end of 2022. The price of one injection will cost 2.8 million dollars, which is enough to completely eliminate the symptoms," the information said.

Note that beta thalassemia is an inherited disease caused by several different mutations that reduce the production of hemoglobin in red blood cells.